This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Jefferies Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
In a report released today, from Jefferies maintained a Buy rating on Supernus Pharmaceuticals, with a price target of $60.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $61.60.
Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $192.1 million and a GAAP net loss of $45.12 million. In comparison, last year the company earned a revenue of $175.69 million and had a net profit of $38.5 million
Read More on SUPN:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
